fpi-2265
fpi-2265: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Fusion Pharmaceuticals Inc. (FUSN) | Phase 2 |
Clinical Trials (1)
PSMA-directed Targeted Alpha Therapy With FPI-2265 (225Ac-PSMA-I&T) for the Treatment of Metastatic Castration-resISTant Prostate Cancer (TATCIST). A Phase II Clinical Trial.
Frequently asked questions
Who is developing fpi-2265?
fpi-2265 is being developed by Fusion Pharmaceuticals Inc..
How many clinical trials involve fpi-2265?
BioSniper tracks 1 clinical trial involving fpi-2265.
Get deeper analysis on fpi-2265
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis